Search filters

Filters
Clear All

Phase

  • 67
  • 68
  • 1
  • 81
  • 60
  • 13
  • 190
  • 556
  • 217
  • 9
  • 22
  • 528
  • 556
  • 3

Found 559 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 99 years
All genders
Phase 2
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …
 PRELIMINARY STUDY OF OPTICAL BIOMARKERS FOR NEURODEGENERATION IN CHRONIC CEREBROVASCULAR DISEASE
99 years or below
All genders
This research study will test whether a new optical device can reliably measure markers of blood flow and blood vessel function in the brain. We will be recruiting 60 subjects in total: 30 healthy, 15 with known narrowing of the carotid artery, and 15 small vessel stroke. All subjects will …
 A Randomized   Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+)  HER2 (-) Breast Cancer
18 years - 99 years
All genders
Phase 3
Interventional
The purpose of the study is to evaluate whether SAR439859 (an experimental hormonal treatment), in combination with palbociclib is a better option compared to letrozole (a standard hormonal treatment), in combination with palbociclib, in terms of efficacy and tolerance for treating patients with ER (+), HER2 (-) breast cancer. Eligible …
16 years - 35 years
Female
Phase 3
Interventional
The Women's Health Clinical Research Center at University of Pennsylvania is currently recruiting healthy women who have regular periods and do not wish to become pregnant for at least 12 months for a research study of an investigational birth control patch. The study patch that will be used in this …
 A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
18 years - 98 years
All genders
Phase 2
The BBI-DSP-7888-201G trial is designed to compare the overall survival (OS) between treatment with DSP-7888 Dosing Emulsion plus bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following initial therapy. This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study. Approximately 200 patients …
99 years or below
All genders
The purpose of this study is to evaluate the performance of the EchoMark and EchoSure (both FDA approved devices) as an ultrasound-based method of monitoring the viability of free flaps and patency of at-risk vessels. The implant and ultrasound will be used per IFU. The primary purpose of the study …
 Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
18 years - 99 years
All genders
Phase 1
Interventional
This research study consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be …
 TEGSEDI study
18 years - 99 years
All genders
Phase 4
This research study is being done at the request of the US Food & Drug Administration (FDA) to collect additional safety information for the commercially available drug TEGSEDI. This research study is being conducted to examine any changes in health or side effects occurring within 24 hours following treatment with …
18 years - 99 years
All genders
Interventional
This is a dose range finding safety study of Branaplam administered as weekly oral doses in participants with early manifest HD. The study aims to explore a range of doses to select a safe and tolerable dose that lowers mutant huntingtin protein (mHTT) levels in the CSF to a degree …
99 years or below
All genders
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination …
411 - 420 of 559